# Xeris Biopharma Holdings, Inc. (XERS)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1.16B  
**Price:** $6.71 (+3.23%)

> Xeris Biopharma Holdings, Inc. is a biopharmaceutical company headquartered in Chicago, Illinois. It specializes in developing and commercializing therapies for chronic endocrine and neurological conditions, with a commercial portfolio featuring three key products: Recorlev for treating endogenous Cushing's syndrome in adults unsuitable for surgery, Gvoke for severe hypoglycemia, and Keveyis for Primary Periodic Paralysis. The company leverages proprietary XeriSol and XeriJect formulation platforms to enable innovative subcutaneous and ready-to-use injectable delivery systems, including the recent commercial launch of Gvoke VialDx, a concentrated liquid glucagon for diagnostic use in radiologic procedures via a partnership with American Regent. Xeris Biopharma Holdings, Inc. maintains an active pipeline, highlighted by XP-8121, a novel levothyroxine formulation for potential endocrine applications, supported by recent U.S. patent allowances. These efforts position the company as a focused player in rare disease treatments within the biotechnology sector, emphasizing patient access, intellectual property protection, and commercial expansion in the U.S. market.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $292M | — | $25M | $554,000 | — |
| 2024 | $203M | — | -$34M | -$55M | — |
| 2023 | $164M | — | -$44M | -$62M | — |
| 2022 | $110M | — | -$82M | -$95M | — |
| 2021 | $50M | — | -$115M | -$123M | — |
| 2020 | $20M | — | -$84M | -$91M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $384M | $370M | $14M | $111M | $220M |
| 2024 | $323M | $353M | -$30M | $72M | $232M |
| 2023 | $323M | $329M | -$7M | $67M | $191M |
| 2022 | $345M | $299M | $45M | $122M | $187M |
| 2021 | $304M | $209M | $95M | $67M | $88M |
| 2020 | $159M | $125M | $34M | $38M | $87M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $29M | — | — |
| 2024 | -$37M | — | — |
| 2023 | -$47M | — | — |
| 2022 | -$103M | — | — |
| 2021 | -$96M | $1M | -$97M |
| 2020 | -$81M | $377,000 | -$81M |

Source: [CompaniesByCap](https://companiesbycap.com/company/XERS)